RenovoRx, Inc.RNXTReports Thu, Nov 5 · Third Quarter 2026
Key ratios
FCF / Sales
-977.3%2025
2024
-21256.0%
ROA
-64.9%TTM
2025
-92.6%2024
-143.1%2023
-163.2%
ROE
-225.6%2025
2024
-1192.7%2023
-647.0%
Revenue growth
2511.6%2025
Recent news
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
Track RNXT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer